{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aravive, Inc."},"Symbol":{"label":"Symbol","value":"ARAV"},"Address":{"label":"Address","value":"3730 KIRBY DRIVE RIVER OAKS TOWER, SUITE 1200, HOUSTON, Texas, 77098, United States"},"Phone":{"label":"Phone","value":"+1 936 355-1910"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Aravive's lead candidate is batiraxcept, which is is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway."},"CompanyUrl":{"label":"Company Url","value":"https://www.aravive.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Amy Franke","title":"Vice President-Clinical Operations"},{"name":"Gail Frances McIntyre","title":"President, Chief Executive Officer &amp; Director"},{"name":"Leonard Scott Dove","title":"Chief Operating Officer"},{"name":"Robert B. Geller","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}